Phase 3 Recruiting Network
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…
Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Children's National Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Network
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …
Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Children's National Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had…
Sponsor: BeOne Medicines
NCT ID: NCT06973187
Sites in District of Columbia: - Medstar Georgetown University Hospital — Washington D.C., District of Columbia
Phase 2 Recruiting NIH
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03739814
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting NIH
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Academic/Other
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-…
Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
NCT ID: NCT05849662
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Academic/Other
This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR. The dose de-escalation will be one dose given on…
Sponsor: Georgetown University
NCT ID: NCT04990102
Sites in District of Columbia: - Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
Phase 1 Recruiting Academic/Other
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims …
Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
NCT ID: NCT05476770
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 1 Recruiting Academic/Other
This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, mole…
Sponsor: University of Oklahoma
NCT ID: NCT03633955
Sites in District of Columbia: - Children's National Health System — Washington D.C., District of Columbia
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
Recruiting Network
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated i…
Sponsor: Children's Oncology Group
NCT ID: NCT00736749
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Children's National Medical Center — Washington D.C., District of Columbia
NA Recruiting Academic/Other
This study aims to determine the impact of massage therapy for pediatric patients receiving intensive chemotherapy or stem cell transplant (SCT).
Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT06892158
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other
This is a multicenter pilot randomized controlled trial, with an active control condition, of the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a cohort of survivors of acute lymphoblastic leukemia or brain tumor ag…
Sponsor: Children's National Research Institute
NCT ID: NCT05528939
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other
Over 90% of children and adolescents diagnosed with acute lymphoblastic leukemia (ALL) will survive long term. Part of the successful treatment that patients receive is the delivery of chemotherapy directly into their spinal fluid via a sp…
Sponsor: Children's National Research Institute
NCT ID: NCT06722638
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia